What is Nephros?
Founded in 1997 and headquartered in South Orange, New Jersey, Nephros develops and markets advanced liquid purification filters, known as ultrafilters. These devices are critical in healthcare settings, primarily used in hospitals and medical clinics to enhance infection control by filtering bacteria, viruses, and endotoxins from water sources like showers and sinks. Nephros's technology also serves dialysis centers, where its ultrafilters assist in removing biological contaminants from water and bicarbonate concentrate used in hemodialysis machines, thereby improving patient safety. The company's focus on critical water purification solutions positions it as a key player in healthcare-associated infection prevention and patient care.
How much funding has Nephros raised?
Nephros has raised a total of $20.3M across 6 funding rounds:
Stock Offering
$12.6M
Share Placement
$1.3M
Share Placement
$1.2M
Share Placement
$2.9M
Share Placement
$2M
Debt
$350K
Stock Issuance/Offering (2004): $12.6M, investors not publicly disclosed
Share Placement (2009): $1.3M led by Undisclosed
Share Placement (2015): $1.2M, investors not publicly disclosed
Share Placement (2018): $2.9M, investors not publicly disclosed
Share Placement (2019): $2M, investors not publicly disclosed
Debt (2020): $350K with participation from PPP
What's next for Nephros?
The recent major strategic investment signifies a pivotal moment for Nephros, likely enabling the company to accelerate product development, expand its market reach, and bolster its commercial operations. Given the enterprise-level context of its total funding, Nephros appears poised for significant scaling, potentially exploring new applications for its ultrafilter technology or strengthening its presence in existing markets. This strategic backing is expected to fuel further innovation and solidify Nephros's role in enhancing water safety and infection control within healthcare environments.
See full Nephros company page
